Pfizer’s pricing deal with the Trump administration, which won the company a three-year exemption from sector-specific ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Concerns about the company's future growth are likely keeping investors away.

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...